Abcuro Adds $66M to Try Again in Rare Inflammatory Disorder With No Approved Drugs
Abcuro will apply the capital to a study that could support a biologics license application in inclusion body myositis, a rare inflammatory disorder that leads to worsening muscle weakness. A Phase 2/3 study failed earlier this year, but Abcuro saw positive trends in patients with less severe disease.
Cityblock to Acquire Homeward Health, Secures $116M Series E
Cityblock Health plans to acquire rural healthcare provider Homeward Health and has raised $116 million to expand its value-based care model to rural and Medicare Advantage populations.
How to Prepare Your Hospital Before H.R. 1 Hits in 2027
But the deadline that most people are not tracking, and the most worrisome, is October 1, 2026. It’s the day federal Medicaid funding ends for the country’s most vulnerable populations, including refugees, asylees, and humanitarian parolees.
This Week In Epic News: FTC Probe, AI Agents & More
Epic faced an FTC antitrust probe this week, but that didn't stop the EHR giant from unveiling a wave of new AI tools at its annual conference.
Ambros Therapeutics’ Path for Pain Drug Goes Through Reverse Merger With Werewolf
Along with Ambros Therapeutics’ merger with Werewolf Therapeutics, the combined company will raise $150 million in a private placement. Ambros is in Phase 3 testing with a drug developed for treating a type of pain that does not respond to currently available medicines, including opioids.